Currency In USD
| Previous Close | 54.65 |
| Open | 54.52 |
| Day High | 54.65 |
| Day Low | 54.52 |
| 52-Week High | 58.4 |
| 52-Week Low | 21.34 |
| Volume | 11.61M |
| Average Volume | 2.56M |
| Market Cap | 4.5B |
| PE | -14.57 |
| EPS | -3.75 |
| Moving Average 50 Days | 53.06 |
| Moving Average 200 Days | 48.19 |
| Change | 0 |
Data not available
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 07, 2025 12:00 PM GMT
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH Digital patholo
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 07, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need,
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Aug 28, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need,